Leducq Foundation

The Leducq Foundation is a philanthropic organization dedicated to improving human health through international efforts against cardiovascular disease and stroke. It forms part of a broader Leducq organization that includes charitable entities based in the Bahamas, a United States private foundation organized under section 501(c)(3) of the Internal Revenue Code, the Boston-based venture-philanthropy organizations Broadview Ventures and Longview Healthcare Ventures, and an administrative corporation. The organization’s work combines grant-making for scientific research with targeted investment in technologies that may improve the diagnosis or treatment of cardiovascular and neurovascular conditions. The foundation was established in Paris in November 1996 by French entrepreneur Jean Leducq and his wife, Sylviane Leducq. Jean Leducq built an international linen-supply business over several decades, with operations in Europe through ELIS and in North America through RUS. The couple initially created the foundation to support medical research internationally. Its focus subsequently narrowed toward heart disease and stroke. Before the creation of its signature network program, the foundation awarded approximately $30 million in single-investigator grants in 1999 and 2001. In 2003, Leducq launched the Transatlantic Networks of Excellence in Cardiovascular Research, later renamed the International Networks of Excellence, or INE. The program supports large, multinational collaborations involving basic and translational research. Network leaders must come from different continents, and participation is open to investigators worldwide. The program was originally centered on North American and European researchers, reflecting the founders’ connections to those regions, but it later expanded globally. A Scientific Advisory Committee, composed equally of North American and European experts in cardiology, cardiac surgery, and neurovascular medicine, evaluates the scientific merit of applications. Since 2003, the organization has distributed or committed more than $500 million through the INE program, according to reference material. The program has historically made an average of about four awards per year, with a current award described as $8 million over five years. These grants support research across coronary artery disease, heart failure, stroke, cerebral small-vessel disease, cardiac arrhythmias, hypertension, valvular and pulmonary hypertension, and congenital heart disease. Leducq-supported investigators have contributed to work on stem-cell disease models, inflammation in atherosclerosis, renal physiology in hypertension, intracellular cholesterol transport, atrial fibrillation, heart failure, mitral-valve disease, and post-stroke cognitive decline. Following Jean Leducq’s death in 2002, Sylviane Leducq led the foundation as chair or president of its board until her death in 2013. During her tenure, she oversaw the implementation of the INE program and the development of the organization’s venture-philanthropy activities. She received France’s Légion d’honneur in 2009 in recognition of her generosity and leadership. The organization broadened its health agenda in 2021 by making an ongoing commitment to rheumatic heart disease, which remains a major unmet medical need, especially in low- and middle-income countries. Its work in this area includes efforts to identify biomarkers for acute rheumatic fever, support development of vaccines against Group A streptococcal infection, and advance durable, non-thrombogenic prosthetic heart-valve technologies suitable for use in endemic settings. Leducq’s venture activities complement its research grants. Broadview Ventures was created in 2009 to provide seed and early-stage funding to companies developing cardiovascular and stroke technologies. Longview Healthcare Ventures was established in 2018 as a later-stage investment program for selected Broadview companies, particularly clinical-stage businesses raising Series B or Series C financing. Investment returns are intended to support additional investments or further Leducq programs. The organization also includes Ehlers Estate, a Napa Valley vineyard whose bequest supports the philanthropic mission. The foundation is therefore best understood not as a consumer brand, but as the grant-making and research-focused public identity of an international medical-philanthropy network.

Jean and Sylviane Leducq established Fondation Leducq in Paris in November 1996 to support medical research conducted in an international context. Jean Leducq was a French entrepreneur who built a multinational linen-supply business over approximately five decades, operating in Europe through ELIS and in North America through RUS. The founders’ philanthropic interests later concentrated on cardiovascular disease and stroke, two fields in which international cooperation was considered particularly valuable. The foundation’s early grant-making included approximately $30 million in single-investigator awards made in 1999 and 2001. In 2003, it introduced its principal collaborative program, initially called the Transatlantic Networks of Excellence in Cardiovascular Research. The initiative funded cross-border research teams working on cardiovascular disease and stroke. Its original geographic emphasis reflected the Leducqs’ lives in Europe and North America, but the program was subsequently renamed the International Networks of Excellence and opened to investigators worldwide. Its design requires network leadership from different continents, encouraging sustained international cooperation between laboratories and clinical research groups. Jean Leducq died in 2002. Sylviane Leducq subsequently served as president of the board until her death in 2013. She supervised the expansion of the network-grant program and helped establish the foundation’s venture-philanthropy model. In 2009, she received the Légion d’honneur for her philanthropic contribution and leadership. The Leducq structure developed beyond a single grant-making foundation. It includes the Leducq Charitable Trust and Leducq Foundation, both associated with the Bahamas; the Leducq Foundation for Cardiovascular Research in the United States, a private foundation recognized under section 501(c)(3); Broadview Ventures, a Boston-based organization making targeted investments in cardiovascular and stroke technologies; Longview Healthcare Ventures; and the Leducq Corporation, which provides administrative services. Ehlers Estate, a Napa Valley vineyard received through a bequest from the Leducq family, also contributes to the organization’s philanthropic mission. The International Networks of Excellence became the organization’s defining program. Since 2003, Leducq has distributed or committed more than $500 million to it, with an average of approximately four awards per year described in reference material. Current awards are described as $8 million over five years. Scientific applications are assessed by a Scientific Advisory Committee with equal North American and European representation and expertise spanning cardiology, cardiac surgery, and neurovascular medicine. Research supported through the Leducq network has covered coronary artery disease, heart failure, stroke, cerebral small-vessel disease, arrhythmias, hypertension, valvular disease, pulmonary hypertension, and congenital heart disease. Reported scientific contributions include disease modeling with stem cells, research into inflammation and atherosclerosis, studies of renal physiology in hypertension, investigations of intracellular cholesterol transport, identification of calcium/calmodulin-dependent protein kinase II as an important signaling node in atrial fibrillation and heart failure, new models of mitral-valve disease, and work linking inflammation with cognitive decline after stroke. In 2021, Leducq made an ongoing commitment to rheumatic heart disease. The initiative addresses a condition that disproportionately affects low- and middle-income countries and includes three main strands: finding biomarkers for acute rheumatic fever, developing a vaccine against Group A streptococcal infection, and creating durable, non-thrombogenic prosthetic valves that could be deployed at scale. Through Broadview and Longview, the organization also supports translation of research into products and companies, combining grants with seed, early-stage, and later-stage mission-driven investment.

• 2021

  Rheumatic heart disease initiative begins

  [1]Leducq Foundationen.wikipedia.org

  Leducq began an ongoing commitment covering biomarkers, vaccine development, and improved prosthetic valves for rheumatic heart disease.

• 2018

  Longview Healthcare Ventures established

  [1]Leducq Foundationen.wikipedia.org

  A later-stage investment program was created to support selected Broadview companies, particularly clinical-stage businesses seeking follow-on capital.

• 2013

  Death of Sylviane Leducq

  [1]Leducq Foundationen.wikipedia.org

  Sylviane Leducq died after overseeing the development of the international grant program and venture-philanthropy activities.

• 2009

  Broadview Ventures created

  [1]Leducq Foundationen.wikipedia.org

  The Leducq Charitable Trust established a mission-driven investment organization for seed and early-stage cardiovascular and stroke technologies.

• 2009

  Sylviane Leducq receives the Légion d’honneur

  [1]Leducq Foundationen.wikipedia.org

  France honored Sylviane Leducq for her generosity and leadership of the foundation.

• 2003

  Transatlantic Networks of Excellence launched

  [1]Leducq Foundationen.wikipedia.org

  Leducq created its signature international cardiovascular research-network program, later renamed the International Networks of Excellence.

• 2002

  Death of Jean Leducq

  [1]Leducq Foundationen.wikipedia.org

  Jean Leducq died, after which Sylviane Leducq continued leading the foundation’s board.

• 1999

  Early single-investigator grants awarded

  [1]Leducq Foundationen.wikipedia.org

  The foundation began a substantial early grant program, later described as totaling about $30 million across awards made in 1999 and 2001.

• 1996

  Fondation Leducq established

  [1]Leducq Foundationen.wikipedia.org

  Jean and Sylviane Leducq created the Paris-based foundation to support international medical research.

A science-led international philanthropic platform that funds cross-border cardiovascular and neurovascular research while helping translate promising medical technologies toward clinical use.

• Research grant program · 2003

  International Networks of Excellence

  The foundation’s flagship program funds multinational teams conducting basic and translational research in cardiovascular and neurovascular disease. Network leaders must be based on different continents, and applications are reviewed by a scientific advisory committee with expertise in cardiology, cardiac surgery, and neurovascular medicine. The program began as a transatlantic initiative and now accepts investigators globally.

• Medical research initiative · 2021

  Rheumatic Heart Disease Initiative

  This initiative addresses rheumatic heart disease, especially in low- and middle-income countries. Its stated priorities include finding biomarkers for acute rheumatic fever, supporting a vaccine against Group A streptococcal infection, and developing durable, non-thrombogenic prosthetic heart valves suitable for broader deployment.

• Venture philanthropy · 2009

  Broadview Ventures

  Broadview Ventures provides seed and early-stage funding to companies developing technologies for diagnosing or treating cardiovascular disease and stroke. It is mission-driven rather than commercially oriented, with investment returns intended to support additional investments or Leducq philanthropic programs.

• Later-stage venture philanthropy · 2018

  Longview Healthcare Ventures

  Longview Healthcare Ventures complements Broadview by making later-stage follow-on investments in selected portfolio companies. Its focus is on clinical-stage businesses, particularly those approaching significant milestones in Series B or Series C financing rounds.

• 2021

  Expand into rheumatic heart diseaseStrategy

  Background

  Rheumatic heart disease represents a significant unmet medical need, with a particularly heavy burden in low- and middle-income countries.

  Action taken

  The foundation made an ongoing commitment to biomarker discovery, Group A streptococcal vaccine development, and improved prosthetic-valve technology.

  Aftermath

  The initiative broadened Leducq’s disease portfolio beyond its established cardiovascular and neurovascular research networks.

  Source

• 2018

  Establish a later-stage investment complementStrategy

  Background

  Broadview’s seed and Series A focus left a need for follow-on support as selected companies progressed toward clinical and value-creating milestones.

  Action taken

  The Leducq Charitable Trust developed Longview Healthcare Ventures for later-stage investments, including Series B and Series C situations.

  Aftermath

  Longview created a second financing channel within the organization’s venture-philanthropy structure.

  Source

• 2009

  Add venture philanthropy to the grant-making modelStrategy

  Background

  The organization wanted to accelerate development of promising technologies for cardiovascular disease and stroke.

  Action taken

  The Leducq Charitable Trust created Broadview Ventures to provide targeted seed and early-stage investments.

  Aftermath

  The organization developed an investment pathway intended to complement research grants and recycle returns into further mission-driven activity.

  Source

• 2003

  Create an international collaborative research-network programStrategy

  Background

  The foundation sought to move beyond single-investigator awards and support sustained cooperation in cardiovascular and stroke research.

  Action taken

  It launched the Transatlantic Networks of Excellence program, later renamed the International Networks of Excellence and expanded to researchers worldwide.

  Aftermath

  The network program became the foundation’s principal grant-making vehicle and has received more than $500 million in distributed or committed support since its creation.

  Total INE funding distributed or committed. More than $500 million (Since 2003)

  Source

1. 1Leducq Foundationen.wikipedia.org
2. 2Leducq Foundation official websitefondationleducq.org